OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer filing on Form 20-F, furnished this Form 6-K on August 29, 2023. The report covers a Nasdaq listing-compliance update rather than operating or financial results.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other operating performance metrics.
Material Change
Nasdaq notified OKYO that it had regained compliance with the minimum $35 million market value requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2), also known as the Market Value Rule.
Outlook, Risks, and Unusual Items
Regaining compliance removes the specific market-value deficiency identified in the filing. The filing does not provide financial guidance, operational outlook, clinical-development updates, or details regarding the duration or basis of the restored compliance.
The announcement was furnished as Exhibit 99.1 and was not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Items
- Verify the basis and effective date of Nasdaq's determination that OKYO regained compliance.
- Review Exhibit 99.1 for any additional conditions, monitoring requirements, or subsequent compliance obligations.
- Consult the company's latest Form 20-F and subsequent reports for cash resources, financing needs, operating results, and other listing risks.
- Confirm whether OKYO remains compliant with all other Nasdaq continued-listing requirements.